MedTrace Logo

VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients

NCT02113033 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-03-13

No results posted yet for this study

Summary

The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation for the treatment of congestive heart failure with reduced ejection fraction, and to report secondary measures of efficacy.

Conditions

  • Heart Failure With Reduced Ejection Fraction

Interventions

DEVICE

Equilia® Vagal Nerve Stimulation

Vagal Nerve Stimulation synchronized with cardiac activity

Sponsors & Collaborators

  • LivaNova

    lead INDUSTRY

Principal Investigators

  • Albert Hagege, MD, PhD · HEGP - Paris, France

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-07
Primary Completion
2016-02-22
Completion
2016-09-20

Countries

  • Belgium
  • France
  • Norway
  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02113033 on ClinicalTrials.gov